12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Syncria albiglutide: Completed Phase III enrollment

GlaxoSmithKline disclosed in its 4Q10 earnings that it completed enrollment of about 500 patients in an open-label, international Phase III trial comparing Syncria in combination with Lantus...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >